Abstract
Purpose: To study the clinical effect of combining insulin aspart with different drugs in the treatment oftype 2 diabetes mellitus (T2DM).Methods: Two hundred and thirty-seven T2DM patients admitted to the Endocrinology Department of the Second Affiliated Hospital of Kunming Medical University from March to September 2018 were selected as subjects in this study. Miglitol and metformin were used in combination with insulin aspart in the treatment of T2DM. In addition, data on the effectiveness and safety of different treatment options,such as patient’s weight, waist circumference, blood glucose indicators, indices of heart, liver and kidney functions, and incidence of complications were recorded and compared between the two groups.Results: The use of a combination of miglitol and insulin aspart produced an excellent hypoglycaemic effect, and it significantly reduced the incidence of sensory neuropathy in the eyes and distal limbs (p < 0.05). The use of combination of metformin and insulin aspart effectively protected the heart and kidney, and prevented hypoglycaemia (p < 0.05).Conclusion: These results suggest that treatment with a combination of miglitol and insulin aspart is suitable for patients with T2DM whose blood sugar levels are out of control, while combined treatment with metformin and insulin aspart is more suited for patients who desire to reduce blood sugar and blood lipids through weight loss, and patients with cardiac and renal insufficiency.
Highlights
Type 2 diabetes mellitus (T2DM) is a complex chronic metabolic disease induced by genetic and environmental factors [1,2]
Patients in the following categories were excluded from the study: non-T2DM patients, those with severe heart disease, liver and kidney dysfunction; patients who were allergic to metformin, insulin aspart, or miglitol, as well as those who had malignant tumours
In the metformin + IA50 group, there were 3 cases of hypoglycaemia, 5 cases of nausea and vomiting, 1 case of rash, and 9 cases of abdominal pain, with 15.13 % incidence of adverse reactions (Figure 5 B). These results indicate that the miglitol + IA50 combination was marginally safer than metformin + IA50
Summary
Type 2 diabetes mellitus (T2DM) is a complex chronic metabolic disease induced by genetic and environmental factors [1,2]. The major manifestations of T2DM are insulin resistance, hyperglycaemia, and multiple complications (atherosclerosis, ocular retinopathy, acute myocardial infarction, and cerebral ischaemic stroke). These characteristics seriously endanger the health and life of T2DM patients and impose heavy burdens on the society and economy. Insulin aspart has some drawbacks such as rapid elimination rate and short mean residence time [8]. These impose a need for frequent application of the drug, which significantly increases the risk of hypoglycaemia. There is need for development of safer and more effective treatment strategies for T2DM
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
